

**Studies on the use of
glycosaminoglycans for the
treatment of Alzheimer's disease**

**Hao Cui
MPharmSc**

Submitted in fulfilment of the requirements for the
degree of Doctor of Philosophy

University of Tasmania

10/2012

DECLARATION OF ORIGINALITY

This thesis contains no material that has been accepted for the award of any other degree or diploma in any other tertiary institution.

To the best of my knowledge and belief, this thesis contains no material previously published or written by any other person except where due reference is made in the text of the thesis

08.10.2012

AUTHORITY OF ACCESS

This thesis may be available for loan and limited copying in accordance
with the Copyright Act 1968

08.10.2012

Table of Contents

Abstract	i
Acknowledgements	v
List of Abbreviations	vii
Publication record	xii
Chapter 1. Literature review and introduction	1
1.1 Alzheimer's disease	2
1.2 Pathology of AD	2
1.2.1 Neurofibrillary tangles (NFTs)	3
1.2.2 Amyloid plaque	4
1.2.3 Cerebral amyloid angiopathy (CAA)	5
1.2.4 Synaptic loss	6
1.3 Aβ peptide	7
1.3.1 A β aggregation	9
1.3.2 Soluble A β oligomer production and toxicity	10
1.3.3 A β -induced calcium dysregulation	13
1.3.4 Physiological function of A β	15
1.4 Biology of amyloid precursor protein (APP)	16
1.4.1 Structure of APP	17

1.4.2 Functions of APP	20
1.4.2.1 Cell adhesion	20
1.4.2.2 Role as a cell surface receptor	21
1.4.2.3 Role in neurite outgrowth, synaptogenesis and neuroprotection	22
1.4.2.4 Interaction of APP with adapter proteins	24
1.4.2.5 Non-neuronal function of APP	27
1.4.3 Proteolytic processing of APP	28
1.4.3.1 APP trafficking and processing	28
1.4.3.2 APP processing secretases	29
1.4.3.2.1 α -secretase cleavage	29
1.4.3.2.2 β -secretase cleavage	30
1.4.3.2.3 γ -secretase cleavage	32
1.5 Genetics and risk factors for AD	33
1.5.1 Early onset AD (familial AD)	34
1.5.1.1 APP mutations	34
1.5.1.2 Presenilin mutations	36
1.5.2 Late onset AD (sporadic AD)	37
1.5.2.1 ApoE	38
1.5.2.2 Clusterin (apoJ)	43
1.5.2.3 Bridging integrator 1 (BIN1)	45
1.5.2.4 ATP-binding cassette transporter A7 (ABCA7)	46
1.6 Mouse models of AD	47
1.6.1 Transgenic mouse models of AD	48
1.6.2 APP knockout mice	52
1.7 Current and prospective AD therapies	53

1.7.1 Current therapeutic approaches of AD	54
1.7.1.1 Acetylcholinesterase (AChE) inhibitors	54
1.7.1.2 Memantine	55
1.7.2 Prospective therapeutic strategies in AD	56
1.7.2.1 A β aggregation inhibitors	56
1.7.2.2 A β immunotherapy	59
1.7.2.3 Suppression of A β production	60
1.7.2.3.1 β -secretase inhibitors	61
1.7.2.3.2 γ -secretase inhibitors	61
1.7.2.3.3 Statins	63
1.7.2.4 Non-A β -based approaches	63
1.8 Proteoglycans	64
1.8.1 Structure of proteoglycans and glycosaminoglycans	65
1.8.2 Synthesis and modification of proteoglycans	67
1.8.3 Expression of proteoglycans in the brain	68
1.8.3.1 Chondroitin sulfate proteoglycans (CSPGs)	68
1.8.3.2 Heparan sulfate proteoglycans (HSPGs)	72
1.8.4 Function of proteoglycans in the brain	73
1.8.4.1 Function of proteoglycans in the CNS development	74
1.8.4.1.1 Chondroitin sulfate proteoglycans	74
1.8.4.1.2 Heparan sulfate proteoglycans	76
1.8.4.2 Function of proteoglycans in plasticity	77
1.8.4.3 Function of proteoglycans in synaptogenesis	78
1.8.4.4 Function of proteoglycans in brain injury	79
1.8.5 Proteoglycans in neurodegeneration	80

1.8.6	Proteoglycans and GAGs in AD	81
1.8.6.1	PGs in AD pathology	81
1.8.6.2	Roles of PGs in AD	83
1.8.6.2.1	Interaction with APP	83
1.8.6.2.2	Interaction with A β	83
1.8.6.2.3	PGs or GAGs on A β aggregation	84
1.8.6.2.4	Interaction with tau protein	84
1.8.6.3	Potential therapeutic implications	85
1.9	Hypothesis and aims	88
Chapter 2.	Effect of heparin and enoxaparin on APP processing and Aβ production in primary cortical neurons from Tg2576 mice	89
2.1	Introduction	90
2.2	Materials and methods	92
2.2.1	Materials	92
2.2.2	Cell culture	93
2.2.3	SDS-PAGE and western blotting	93
2.2.4	Quantitative real-time PCR	96
2.3	Results	97
2.3.1	Effect of heparin and enoxaparin on A β	97
2.3.2	Characterisation of APP C-terminal fragments (CTFs)	97
2.3.3	Effects of heparin and enoxaparin on levels of APP, sAPP α and CTFs	104
2.3.4	Effects of heparin on the level of BACE1, ADAM10 and ADAM17	107
2.3.5	Effects of heparin fragments on A β secretion	108
2.4	Discussion	111

Chapter 3. Size and sulfation are critical for the effect of heparin on APP processing and Aβ production	117
3.1 Introduction	118
3.2 Materials and methods	119
3.2.1 Materials	119
3.2.2 Primary cortical cell culture	121
3.2.3 SDS-polyacrylamide gel electrophoresis and western blotting	121
3.3 Results	122
3.3.1 Effects of heparin fragments on APP processing	122
3.3.2 Effects of different class of GAGs on APP processing and A β production	125
3.3.3 Effects of selectively desulfated and decarboxylated heparin on APP processing	128
3.4 Discussion	133
Chapter 4. Effects of enoxaparin on APP processing and Aβ production in Tg2576 mice	137
4.1 Introduction	138
4.2 Materials and methods	139
4.2.1 Materials	139
4.2.2 Animal and ENO treatment	139
4.2.3 Immunohistochemistry	140
4.2.4 SDS-PAGE and western blotting	141
4.3 Results	142
4.3.1 Effects of ENO on the level of A β	142

4.3.2 Effects of ENO on levels of APP, APP C-terminal fragments and APP cleavage enzymes	142
4.3.3 Effect of ENO on the number of amyloid plaques and on total amyloid load	148
4.4 Discussion	150
Chapter 5. Effects of endogenous heparan sulfate on APP processing and Aβ production	157
5.1 Introduction	158
5.2 Materials and methods	160
5.2.1 Materials	160
5.2.2 Primary cortical cell culture	160
5.2.3 Western blotting of cell lysates and media	160
5.2.4 Immunocytochemistry	161
5.2.5 Heparin affinity chromatography	162
5.3 Results	162
5.3.1 Effects of endogenous HS on APP processing and A β production	162
5.3.2 Heparin chromatography of ADAM10	167
5.4 Discussion	169
Chapter 6. Discussion	173
6.1 A possible mechanism of the effect of GAG derivatives on APP processing	182
References	185

Abstract

Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative disorder that is commonly found in the elderly population. AD is characterized pathologically by the deposition of amyloid plaques and neurofibrillary tangles in the brain. The major component of amyloid plaque is the β -amyloid protein ($A\beta$), a 40-42 amino-acid residue polypeptide that is generated from the β -amyloid precursor protein (APP) by the β -site APP cleaving enzyme-1 (BACE1) and γ -secretase. APP can also be cleaved by α -secretase within the $A\beta$ sequence to form sAPP α and C83, which thus precludes formation of $A\beta$.

Advances in AD research over the past three decades have not yet led to effective treatments to prevent or cure AD. Therefore, an effective drug for the treatment of AD is required. As oligomeric forms of $A\beta$ are thought to be the major toxic species which cause AD, therapeutic approaches are now targeting the production, clearance or neurotoxicity of $A\beta$.

It has been reported that glycosaminoglycans (GAGs) such as heparin can influence $A\beta$ production by disrupting APP proteolytic processing. Studies have reported that heparan sulfate and heparin can directly inhibit BACE1 activity in vitro and thereby decrease $A\beta$ production in cell culture. Studies have also shown that heparin binds close to the prodomain of the BACE1 zymogen (proBACE1) and that this binding

stimulates proBACE1 activity. However, heparin can also inhibit mature BACE1 activity by binding close to the active site domain of the mature protein. In contrast, other groups have reported that heparin stimulates β -secretase cleavage of APP in a cultured cell line.

As there are conflicting reports on the effect of GAGs on APP processing and A β production, the effects of heparin or enoxaparin on APP processing was first examined in primary cortical cells obtained from transgenic mice expressing human APP₆₉₅ with the Swedish familial AD mutant (Tg2576 mouse). The results showed that heparin or enoxaparin (ENO) treatment can lower A β secretion from cortical cells by decreasing BACE1 and thereby inhibiting β -secretase processing of APP. Additionally, treatment with heparin or enoxaparin decreased the α -secretase ADAM10 and inhibited α -secretase processing of APP.

The development of GAG analogues which can be used for the treatment of AD will require the identification of highly potent and specific compounds that have the ability to cross the blood-brain barrier (BBB). Therefore, an aim of the studies in this thesis was to examine the structure specificity (molecular size and sulfation degree) of GAGs with the aim of identifying more potent and specific GAG-based compounds to inhibit APP processing and A β production. The effects of various GAGs and sulfated polysaccharides on APP processing were tested in primary cortical cells derived from Tg2576 mice. The results showed that the effect of GAGs on APP processing was both size- and sulfation-dependent. Mucosal heparins (MHs) with small sizes (5 kDa and 3kDa) were less potent in reducing A β than high molecular weight MHs (6 kDa and 12.5 kDa). 6-O-Sulfation was important for the effect on APP processing as

heparin lacking 6-O sulfate were less potent than native heparin. However, deletion of carboxyl groups on MH had no significant effect on APP processing. These data suggest that it might be possible to alter the structure of GAGs to achieve more potent and specific inhibitors of APP processing that can cross the blood-brain barrier.

It has been reported that peripheral administration of ENO can reduce the level of A β and the amyloid plaque load in the brain of APP transgenic mice. However, the exact mechanism of these effects has been unclear. Therefore, an aim of this study was to examine whether the reduced amyloid plaque load reported to occur in the brains of the APP transgenic mice treated with ENO was due to decreased APP processing to A β caused by ENO treatment. ENO was peripherally injected to Tg2576 mice, and the APP processing products and amyloid load in the brains of the mice were examined. The study found that ENO treatment decreased the A β 40/A β 42 ratio in cortex and increased the amyloid plaque load in both cortex and hippocampus, while overall APP processing was not significantly influenced by ENO. The exact mechanism of these effects remains unknown. These results suggest that the strategy of using ENO for the treatment of AD may need further assessment.

As GAGs such as HS are widely expressed in the brain in the form of proteoglycans, it is possible that the endogenous HS may also affect APP processing. Therefore, an aim of the study was to examine the role of endogenous HS on APP processing and A β production. To examine this, primary cortical cells derived from Tg2576 mice were incubated with a drug or enzyme designed to degrade HS chains from endogenous proteoglycans. The results showed that deletion of endogenous HS can

reduce the level of BACE1 and ADAM10 and thus inhibit APP processing through β - and α -secretase cleavage pathways similar to exogenous treatment of heparin. These findings suggest that regulation of endogenous HS to inhibit APP processing to $A\beta$ could be a novel approach for the treatment of AD.

Based on these results, modification of structures of GAGs or sulfate polysaccharides may achieve highly potent and specific BBB-permeable compounds which can inhibit APP processing to $A\beta$. Moreover, regulation of endogenous HS can also affect APP processing and $A\beta$ production. Therefore, the studies reported in this thesis support the view that GAG-based compounds can regulate the $A\beta$ production and strategies based on administration of GAGs or the alteration of endogenous GAG metabolism may have value for the treatment of AD.